A股異動 | 潛能恆信午後直線漲停 全資公司獲得準噶爾盆地九1-九5區塊開發及生產權益
格隆匯11月8日丨潛能恆信(300191.SZ)午後直線漲停,封單逾9萬手,今年以來已累漲逾72%,現報25.3元,暫成交5200萬元,最新總市值81億元。潛能恆信午間發佈公告稱,公司海外全資公司智慧石油投資有限公司通過參與中國石油天然氣集團有限公司組織的對外合作招標,於今日(11月8日)與中國石油簽訂了為期30年的石油產品分成合同,取得了中國準噶爾盆地九1-九5區塊開發和生產權益。此外據悉,潛能恆信第三季度實現歸屬於上市公司股東的淨利潤256.65萬元,同比增長46.97%。10月28日曾公告指,股東張海濤、鄭啟芬通過大宗交易減持股份,山東省國資接盤入股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.